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Abstract
Toll-like receptors (TLRs) are pattern recognition receptors that recognize specific molecular
patterns present in molecules that are broadly shared by pathogens, but are structurally distinct
from host molecules. The TLR7-agonistic imidazoquinolines are of interest as vaccine adjuvants
given their ability to induce pronounced Th1-skewed humoral responses. Minor modifications on
the imidazoquinoline scaffold result in TLR7-antagonistic compounds which may be of value in
addressing innate immune activation-driven immune exhaustion observed in HIV. We describe the
syntheses and evaluation of TLR7 and TLR8 modulatory activities of dimeric constructs of
imidazoquinoline linked at the C2, C4, C8, and N1-aryl positions. Dimers linked at the C4, C8 and
N1-aryl positions were agonistic at TLR7; only the N1-aryl dimer with a 12-carbon linker was dual
TLR7/8 agonistic. Dimers linked at C2 position showed antagonistic activities at TLR7 and TLR8;
the C2 dimer with a propylene spacer was maximally antagonistic at both TLR7 and TLR8.
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Introduction
Toll-like receptors (TLRs) are pattern recognition receptors that recognize specific
molecular patterns present in molecules that are broadly shared by pathogens, but are
structurally distinct from host molecules.1;2 There are 10 TLRs in the human genome.2 The
ligands for these receptors are highly conserved microbial molecules such as
lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in combination with
TLR1 or TLR6), flagellin (TLR5), single stranded RNA (TLR7 and TLR8), double stranded
RNA (TLR3), CpG motif-containing DNA (recognized by TLR9), and profilin present on
uropathogenic bacteria (TLR 11).3;4 TLR1, -2, -4, -5, and -6 respond to extracellular stimuli,
while TLR3, -7, -8 and -9 respond to intracytoplasmic pathogen-associated molecular
patterns (PAMPs), being associated with the endolysosomal compartment.2
We have earlier explored structure activity-relationships in TLR2- and TLR7-active
ligands5;6 toward exploiting them as potential vaccine adjuvants;7;8 the TLR7-agonistic
imidazoquinolines are of particular interest in that they induce pronounced Th1-skewed
humoral responses in animal models.9 Of equal interest is our finding that relatively minor
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modifications on the imidazoquinoline scaffold result in TLR7-antagonistic compounds10;11
which may be of value in addressing the relentless innate immune activation-driven immune
exhaustion observed in HIV.12–14
Several TLRs are thought to signal via ligand-induced dimerization,15 as evident in the
crystal structures of TLR216;17 and TLR3.18 It is not yet understood, however, how TLR7
and TLR8 whose endogenous ligands are single-stranded viral RNA (ssRNA), recognize
and transduce signals upon engagement by small, non-polymeric molecules such as the
imidazoquinolines19;20 and the oxoadenines.21;22 We were not only desirous of examining
the effect of variously configured, pre-organized dimeric constructs of the
imidazoquinolines on TLR7 and TLR8 in our continuing efforts to identify efficacious and
safe vaccine adjuvants, but also motivated in the hope that we may, by design or accident,
discover small-molecule modulators of TLR3. It may be noted that although TLR3, like
TLR7, is an attractive target for adjuvant design and development, 23–28
polyriboinosinic:polyribocytidylic acid, poly(I:C), is presently the only available synthetic
TLR3 agonist. 29 No small molecule agonists for TLR3 have been described to date;
however, benzothiophene antagonists of TLR3 have been reported recently.30
We describe in the paper the syntheses and evaluation of TLR7, -8, and -3 modulatory
activities of dimeric constructs of imidazoquinoline linked at the C2, C4, C8, and N1-aryl
positions. Dimers linked at the C4, C8 and N1-aryl positions were agonistic at TLR7; only
the N1-aryl dimer with a 12-carbon linker was found to be dual TLR7/8 agonistic. The
imidazoquinoline dimers linked at C2 position showed antagonistic activities at TLR7 and
TLR8; the C2 dimer with a 3-carbon spacer was found to be maximally antagonistic at both
TLR7 and TLR8, and its activities were preserved in secondary screens employing human
blood.
Results and Discussion
The majority of TLRs signal via homo- or hetero-dimerization,15 and it was therefore of
interest to examine dimeric constructs with differing geometries. The first series of dimeric
imidazoquinolines were linked at the C2 position and their syntheses necessitated two
different routes. Whereas the hexamethylene- and decamethylene-bridged compounds 6a
and 6b could be conveniently obtained from 5 by a direct, one-step, bis-amidation using the
corresponding dicarboxylic acid chlorides and cyclization (Scheme 1), the shorter chain
analogues were not amenable to this method because of intramolecular cyclization, giving
rise to undesired quinolin-3-yl piperidinediones. This problem was circumvented by first
reacting glutaric or adipic anhydride with 1, which yielded the monocarboxylic
imidazoquinolines 2a and 2b, respectively; these intermediates were taken forward without
purification and reacted again with 1 to afford the C4, C4′-des-amino precursors 3a and 3b
(Scheme 1). Compounds 4a and 4b (with amines at C4 and C4′, respectively) were obtained
by sequential N-oxidation of the quinoline nitrogen, reaction with benzoyl isocyanate to
afford the C4 and C4′ N-benzoyl intermediate and, finally, cleavage of the N-benzoyl group
using sodium methoxide as described by us earlier.5;11
Next, the dimers linked via the C4-NH2 (8a-d) were synthesized by direct SNAr on 7 using
α, ω-bis-amino alkanes (Scheme 2). Similarly, dimers linked at the N1 position on the 4-
aminomethylene benzyl group (10a-c) were obtained using appropriate dicarboxylic acid
chlorides (Scheme 3).
Linking the 13 series of dimers via the quinoline ring required the introduction of an
additional amine at position C8. This was achieved via carefully controlled nitration of 9
using 1.2–1.3 equiv. of HNO3, followed by N-Boc protection of the amine on the N1
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substituent, and subsequent reduction. Dimerization of the 4,8-diaminoimidazoquinoline 12
proceeded smoothly using dicarboxylic acid chlorides as described in the previous schemes.
It is to be noted that the mono-nitro and mono-amino precursors 11 and 12 were also N-Boc
deprotected and tested for TLR-modulatory activities (Table 1).
All compounds were unfortunately found to be inactive in TLR3 reporter gene assays.
However, with the exception of 4 and 6 series of compounds, all other dimers retained
TLR7-agonistic properties, the 10 series being the most potent (Fig. 1); interestingly, only
10c displayed both TLR7 and TLR8 agonism (Fig. 1 and Table 1), pointing to the necessity
of a long linker for dual agonism. The C2-linked dimeric compounds 4a, 4b, 6a, and 6b
unexpectedly showed potent antagonistic activity in both TLR7 and TLR8 assays, with 4a
being most potent (IC50 values of 3.1 and 3.2 μM in TLR7 and TLR8 assays, respectively;
Fig. 2, Table 1). A distinct relationship between linker length and inhibitory potency was not
observed in this series. Given that the propylene linked 4a was the most active compound, it
appeared possible that a shorter homolog with an ethylene linker may further enhance
antagonistic activity; however, the solubility of this compound was intractably poor despite
our attempts at evaluating a variety of salt forms, and we therefore decided not to include it
in our bioassay screens.
Both agonistic and antagonistic compounds were then tested in appropriate secondary
screens employing ex vivo human blood-derived models. The ligation of TLR7 and TLR8
trigger inflammatory responses characterized by the elaboration of type I interferon (IFN-α/
β) by virus-infected cells via activation of downstream NF-κB and IFN-β promoters.31–36
IFN production is a hallmark response underlying cellular antiviral immune responses. It
was desirable to verify that TLR7 agonism that we had observed (Fig. 1) manifested in IFN
production in secondary screens. Using an ex vivo stimulation model using human peripheral
blood mononuclear cells (hPBMC), it was demonstrated that IFN-α was indeed induced in a
dose-dependent, bimodal manner as expected for innate immune responses (Fig. 3).
Compound 10c was found to be the most potent; we surmise that this is due to its dual
TLR7/8 agonistic activity. The 4 and 6 series were quiescent (Fig. 2), consistent with their
apparent antagonistic behavior.
We elected to examine in detail the antagonistic properties of 4a in inhibiting TLR7 and
TLR8- mediated induction of proinflammatory cytokines (Fig. 4) and chemokines (Fig. 5) in
ex vivo models using human blood, since this compound was found to be the most potent
antagonist in the series in primary screens (Table 1). We compared the potency of 4a
alongside chloroquine, which is known to selectively suppress intracellular TLR7, but not
TLR8 signaling via inhibition of endolysosomal acidification.37;38 We found 4a to be a
potent inhibitor of both TLR7 and TLR8-induced cytokine and chemokine release with IC50
values of about 0.05–0.3 μM (Figs 4, 5). TLR8 signaling manifests predominantly in the
induction of pro-inflammatory cytokines such as TNF-α and IL-1β.39;40 Chloroquine, a
TLR7 antagonist, is a feeble inhibitor of TNF-α and IL-1β, while 4a, as would be expected
for a TLR8 antagonist, potently inhibits the production of these proinflammatory cytokines
(Fig. 4), as well as IL-6 and IL-8 which are typically induced secondarily, in an autocrine/
paracrine manner.
The relative specificity of chloroquine in inhibiting TLR7 as well as the dual TLR7/8-
inhibitory activities of 4a are also evident in Schild plots (Fig. 6). Although the relationship
between antagonist concentration and change in EC50 for TLR7 inhibition by 4a is near-
ideal (slope: 1.12, Fig. 6), a distinct deviation from ideal competitive inhibition for TLR8 is
observed (slope: 0.51), suggesting that additional mechanisms for TLR8 inhibition, possibly
allosteric, may be operational. This is being investigated in greater detail.
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In conclusion, we have observed that the C4, C8, and N1-aryl-linked dimers are agonists,
with the last being most potent. The N1-aryl-linked dimers are of particular interest as
potential vaccine adjuvants are currently being evaluated in animal models. The C2-linked
dimers were found to be potently antagonistic at both TLR7 and TLR8 and may be useful as
small molecule probes for examining the effects of inhibiting endolysosomal TLR signaling
in HIV.
Experimental Section
All of the solvents and reagents used were obtained commercially and used as such unless
noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under
reduced pressure using standard rotary evaporators. Flash column chromatography was
carried out using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf
instrument unless otherwise mentioned, while thin-layer chromatography was carried out on
silica gel CCM pre-coated aluminum sheets. Purity for all final compounds was confirmed
to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 mm × 150 mm, 5 μm
analytical reverse phase C18 column with H2O-isopropanol or H2O-CH3CN gradients and an
Agilent ESI-TOF mass spectrometer (mass accuracy of 3 ppm) operating in the positive ion
acquisition mode. All the compounds synthesized were obtained as solids.
Synthesis of Compound 4a: 2,2′-(propane-1,3-diyl)bis(1-benzyl-1H-imidazo[4,5-
c]quinolin-4-amine)
To a solution of 1 (100 mg, 0.4 mmol) in anhydrous THF, were added triethylamine (53 mg,
0.52 mmol) and glutaric anhydride (60 mg, 0.52 mmol) and the reaction vessel was heated
in a microwave for 2 hours at 110 °C. The solvent was then removed under vacuum to
obtain the crude product 2, which was then dissolved in anhydrous DMF and to this
solution, were added HBTU (167 mg, 0.44 mmol), triethylamine (53 mg, 0.52 mmol), 1
(100 mg, 0.4 mmol) and a catalytic amount of DMAP. The reaction mixture was stirred for
12 hours at 90 °C. The solvent was then removed under vacuum and the residue was purified
using column chromatography (12% MeOH/dichloromethane) to obtain the intermediate the
compound 3 (157 mg). To a solution of 3 in solvent mixture of
MeOH:dichloromethane:chloroform (0.1:1:1), was added 3-chloroperoxybenzoic acid (242
mg, 1.4 mmol) and the reaction mixture was refluxed at 45 °C for 40 minutes. The solvent
was then removed and the residue was purified using column chromatography (35 %
MeOH/dichloromethane) to obtain the bis-N-oxide derivative (130 mg). bis-N-oxide
derivative (110 mg, 0.19 mmol) was then dissolved in anhydrous dichloromethane, followed
by the addition of benzoyl isocyanate (96 mg, 0.67 mmol) and heated at 45 °C for 15
minutes. The solvent was then removed under vacuum and the residue was dissolved in
anhydrous MeOH, followed by addition of excess of sodium methoxide and heated at 80 °C
for 2 hours. The solvent was then removed under vacuum and the residue was purified using
column chromatography (50% MeOH/dichloromethane) to obtain the compound 4a (25 mg,
11%). 1H NMR (500 MHz, DMSO) δ 14.30 (s, 2H), 9.48 – 8.30 (bs, 4H), 7.93 (d, J = 8.3
Hz, 2H), 7.77 (d, J = 8.3 Hz, 2H), 7.65 – 7.60 (m, 2H), 7.38 – 7.34 (m, 2H), 7.26 (t, J = 7.6
Hz, 4H), 7.17 (t, J = 7.4 Hz, 2H), 7.03 (d, J = 7.4 Hz, 4H), 5.94 (s, 4H), 3.16 (t, J = 7.2 Hz,
4H), 2.44 – 2.35 (m, 2H). 13C NMR (126 MHz, DMSO) δ 156.22, 148.86, 135.32, 135.30,
133.48, 129.51, 128.93, 127.57, 125.47, 124.72, 124.54, 121.49, 118.31, 112.16, 48.35,
25.21, 24.43. MS (ESI) calculated for C37H32N8, m/z 588.2750, found 589.2860 (M + H)+.
Compound 4b was synthesized similarly as described for compound 4a
4b—1H NMR (500 MHz, DMSO) δ 13.86 (s, 2H), 8.88 (bs, 4H), 7.93 (d, J = 8.2 Hz, 2H),
7.83 – 7.79 (m, 2H), 7.66 – 7.61 (m, 2H), 7.39 – 7.34 (m, 2H), 7.27 (t, J = 7.6 Hz, 4H), 7.18
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(t, J = 7.4 Hz, 2H), 7.01 (d, J = 7.4 Hz, 4H), 5.94 (s, 4H), 2.99 (s, 4H), 1.83 (s, 4H). 13C
NMR (126 MHz, DMSO) δ 156.55, 148.75, 135.38, 133.62, 129.50, 128.95, 127.60, 125.42,
124.74, 124.54, 121.54, 118.48, 112.28, 48.34, 26.49, 26.14. MS (ESI) calculated for
C38H34N8, m/z 602.2906, found 603.3272 (M + H)+ and 302.1705 (M + 2H)2+
Synthesis of Compound 6a: 2,2′-(hexane-1,6-diyl)bis(1-benzyl-1H-imidazo[4,5-c]quinolin-4-
amine)
To a solution of 5 (60 mg, 0.21 mmol) in anhydrous THF, were added triethylamine (54 mg,
0.53 mmol), and suberoyl chloride (23 mg, 0.11 mmol) and the reaction mixture was stirred
for 6 hours. The solvent was then removed under vacuum and the residue was dissolved in
EtOAc and washed with water/brine. The EtOAc fraction was then dried using sodium
sulfate and evaporated under vacuum to obtain the intermediate amide compound, which
was then dissolved in 1 mL solution of 2M ammonia in MeOH and heated at 150 °C for 15
hours. The solvent was then removed under vacuum and the residue was purified using
column chromatography (20% MeOH/dichloromethane) to obtain the compound 6a (8 mg,
12 %). 1H NMR (500 MHz, MeOD) δ 7.96 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 8.4 Hz, 2H),
7.65 (dd, J = 11.5, 4.2 Hz, 2H), 7.39 (t, J = 7.8 Hz, 2H), 7.31 (t, J = 7.4 Hz, 4H), 7.25 (t, J =
7.3 Hz, 2H), 7.06 (d, J = 7.4 Hz, 4H), 5.93 (s, 4H), 2.97 (t, J = 7.5 Hz, 4H), 1.85 (d, J = 7.0
Hz, 4H), 1.43 (s, 4H). 13C NMR (126 MHz, MeOD) δ 158.93, 137.73, 136.20, 135.30,
131.11, 130.47, 129.31, 126.65, 126.57, 125.81, 122.94, 119.65, 114.20, 50.13, 29.70,
27.92. MS (ESI) calculated for C40H38N8, m/z 630.3219, found 631.3415 (M + H)+.
Compound 6b was synthesized similarly as described for compound 6a
6b—1H NMR (500 MHz, MeOD) δ 7.86 (d, J = 8.3 Hz, 2H), 7.69 (d, J = 8.4 Hz, 2H), 7.51
(t, J = 7.7 Hz, 2H), 7.32 (t, J = 7.3 Hz, 4H), 7.28 (d, J = 7.2 Hz, 2H), 7.23 (t, J = 7.7 Hz,
2H), 7.06 (d, J = 7.4 Hz, 4H), 5.88 (s, 4H), 2.96 (t, J = 7.6 Hz, 4H), 1.79 (dt, J = 15.3, 7.7
Hz, 4H), 1.37 (dd, J = 14.9, 7.4 Hz, 4H), 1.32 – 1.24 (m, J = 11.6 Hz, 4H), 1.23 (d, J = 10.1
Hz, 4H). 13C NMR (126 MHz, MeOD) δ 157.44, 151.60, 136.61, 130.41, 129.74, 129.22,
126.69, 126.46, 124.90, 123.38, 122.15, 115.12, 50.05, 30.32, 30.25, 30.17, 28.49, 28.17.
MS (ESI) calculated for C44H46N8, m/z 686.3845, found 687.3749 (M + H)+ and 344.1949
(M + 2H)2+
Synthesis of Compound 8b: N1,N8-bis(1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-
yl)octane-1,8-diamine
To a solution of 7 (50 mg, 0.14 mmol) in 1 mL of anhydrous MeOH, was added 1,8-
diaminooctane (10 mg, 0.07 mmol) and the reaction mixture was heated at 140 °C for 4
hours. The solvent was then removed under vacuum and the residue was purified using
column chromatography (8% MeOH/dichloromethane) to obtain the compound 8b (12 mg,
22%). 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8.3 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.41
(t, J = 7.7 Hz, 2H), 7.36 – 7.26 (m, 6H), 7.09 – 7.01 (m, 6H), 5.78 (s, 2H), 5.72 (s, 4H), 3.77
(dd, J = 12.8, 6.6 Hz, 4H), 2.92 – 2.83 (m, 4H), 1.87 – 1.74 (m, 8H), 1.58 – 1.50 (m, 4H),
1.45 (dt, J = 15.1, 7.5 Hz, 8H), 0.93 (t, J = 7.4 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ
153.34, 150.78, 145.51, 135.62, 129.20, 127.93, 127.41, 127.07, 126.68, 125.59, 121.34,
119.52, 114.87, 48.81, 40.76, 30.18, 29.98, 29.50, 27.21, 22.56, 13.77. MS (ESI) calculated
for C50H58N8, m/z 770.4784, found 771.4963 (M + H)+ and 386.2570 (M + 2H)2+.
Compounds 8a, 8c and 8d were synthesized similarly as described for compound 8b
8a—1H NMR (500 MHz, CDCl3) δ 7.86 (d, J = 8.2 Hz, 2H), 7.65 (dd, J = 8.2, 1.0 Hz, 2H),
7.41 – 7.35 (m, 2H), 7.35 – 7.24 (m, 6H), 7.09 – 6.99 (m, 6H), 5.86 (s, 2H), 5.69 (s, 4H),
3.87 (s, 4H), 2.88 – 2.81 (m, 4H), 2.00 (s, 4H), 1.76 (ddd, J = 13.0, 9.0, 7.7 Hz, 4H), 1.46 –
1.37 (m, 4H), 0.90 (t, J = 7.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 151.27, 148.66,
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143.44, 133.52, 130.85, 128.77, 127.28, 127.13, 125.85, 125.38, 124.95, 124.60, 123.50,
123.40, 119.29, 117.45, 112.81, 46.71, 38.40, 28.01, 25.51, 25.10, 20.47, 11.68. MS (ESI)
calculated for C46H50N8, m/z 714.4158, found 715.4333 (M + H)+ and 358.2263 (M +
2H)2+
8c—1H NMR (500 MHz, CDCl3) δ 7.84 (d, J = 8.2 Hz, 2H), 7.66 (dd, J = 8.2, 1.0 Hz, 2H),
7.40 – 7.36 (m, 2H), 7.33 – 7.26 (m, 6H), 7.07 – 7.01 (m, 6H), 5.73 (s, 2H), 5.70 (s, 4H),
3.74 (dd, J = 12.7, 6.5 Hz, 4H), 2.88 – 2.83 (m, 4H), 1.80 – 1.72 (m, 8H), 1.53 – 1.24 (m,
16H), 0.91 (t, J = 7.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 151.76, 149.23, 143.97,
134.05, 131.32, 127.81, 127.63, 126.36, 125.85, 125.50, 125.10, 124.01, 123.84, 119.75,
117.95, 113.30, 47.23, 39.17, 28.62, 28.39, 28.06, 27.95, 25.65, 20.98, 12.20. MS (ESI)
calculated for C52H62N8, m/z 798.5097, found 799.5416 (M + H)+ and 400.2799 (M +
2H)2+
8d—1H NMR (500 MHz, CDCl3) δ 7.84 (d, J = 8.2 Hz, 2H), 7.65 (dd, J = 8.2, 1.0 Hz, 2H),
7.38 (ddd, J = 8.3, 7.1, 1.3 Hz, 2H), 7.34 – 7.24 (m, 6H), 7.06 – 7.00 (m, 6H), 5.74 (s, 2H),
5.69 (s, 4H), 3.74 (dd, J = 12.6, 6.5 Hz, 4H), 2.86 (dd, J = 17.4, 9.6 Hz, 4H), 1.83 – 1.69 (m,
8H), 1.56 – 1.30 (m, 20H), 0.91 (t, J = 7.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 151.81,
149.27, 144.02, 134.08, 131.36, 127.68, 126.41, 125.87, 125.53, 125.16, 124.05, 119.81,
118.00, 113.34, 47.27, 39.25, 28.65, 28.44, 28.15, 28.13, 28.01, 25.70, 25.68, 21.03, 12.24.
MS (ESI) calculated for C54H66N8, m/z 826.5410, found 827.5796 (M + H)+ and 414.2977
(M + 2H)2+
Synthesis of Compound 10b: N1,N8-bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
yl)methyl)benzyl)octanediamide
To a solution of 9 (25 mg, 0.058 mmol) in anhydrous THF, were added triethylamine (15
mg, 0.15 mmol) and suberoyl chloride (6 mg, 0.029 mmol). The reaction mixture was stirred
for 1 hour and then the solvent was removed under vacuum. The residue was then purified
using column chromatography (30% MeOH/dichloromethane) to obtain the compound 10b
(8 mg, 32%) 1H NMR (500 MHz, MeOD) δ 7.65 (dd, J = 8.3, 0.9 Hz, 2H), 7.55 – 7.51 (m,
2H), 7.27 (ddd, J = 8.3, 7.1, 1.2 Hz, 2H), 7.12 (d, J = 8.2 Hz, 4H), 6.95 (ddd, J = 8.2, 7.2,
1.1 Hz, 2H), 6.88 (d, J = 8.2 Hz, 4H), 5.69 (s, 4H), 4.18 (s, 4H), 2.84 – 2.78 (m, 4H), 2.03 (t,
J = 7.5 Hz, 4H), 1.64 (dt, J = 15.4, 7.6 Hz, 4H), 1.47 – 1.37 (m, 4H), 1.30 (dq, J = 14.8, 7.4
Hz, 4H), 1.16 – 1.10 (m, 4H), 0.80 (t, J = 7.4 Hz, 6H). 13C NMR (126 MHz, MeOD) δ
176.03, 156.18, 152.62, 144.89, 140.08, 136.09, 135.55, 129.44, 128.54, 126.95, 126.86,
126.21, 123.42, 121.58, 115.75, 49.58, 43.58, 36.85, 30.85, 29.75, 27.82, 26.74, 23.43,
14.11. MS (ESI) calculated for C52H60N10O2, m/z 856.4901, found 879.4711 (M + Na+)
and 429.2430 (M + 2H)2+
Compounds 10a and 10c were synthesized similarly as described for compound 10b
10a—1H NMR (400 MHz, MeOD) δ 7.85 (d, J = 7.6 Hz, 2H), 7.68 (d, J = 7.8 Hz, 2H), 7.52
– 7.45 (m, 2H), 7.26 (d, J = 8.2 Hz, 4H), 7.23 – 7.16 (m, 2H), 7.02 (d, J = 8.2 Hz, 4H), 5.85
(s, 4H), 4.30 (s, 4H), 2.99 – 2.93 (m, 4H), 2.19 (t, J = 6.0 Hz, 4H), 1.80 (dd, J = 15.3, 7.7
Hz, 4H), 1.58 (t, J = 3.1 Hz, 4H), 1.45 (dd, J = 15.0, 7.5 Hz, 4H), 0.94 (t, J = 7.4 Hz,
6H). 13C NMR (101 MHz, MeOD) δ 174.28, 156.00, 150.28, 138.78, 135.01, 134.27,
128.13, 128.05, 125.44, 123.28, 121.97, 120.73, 113.67, 48.28, 42.15, 35.17, 29.21, 26.38,
25.03, 21.96, 12.68. MS (ESI) calculated for C50H56N10O2, m/z 828.4588, found 829.4440
(M + H)+ and 415.2244 (M + 2H)2+
10c—1H NMR (500 MHz, MeOD) δ 7.69 (dd, J = 8.3, 0.8 Hz, 2H), 7.54 (dd, J = 8.4, 0.7
Hz, 2H), 7.31 (ddd, J = 8.4, 7.2, 1.2 Hz, 2H), 7.14 (d, J = 8.2 Hz, 4H), 7.00 (ddd, J = 8.2,
7.2, 1.1 Hz, 2H), 6.90 (d, J = 8.2 Hz, 4H), 5.73 (s, 4H), 4.20 (s, 4H), 2.85 – 2.81 (m, 4H),
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2.06 (t, J = 7.4 Hz, 4H), 1.66 (dt, J = 15.4, 7.6 Hz, 4H), 1.44 (dt, J = 14.4, 7.3 Hz, 4H), 1.31
(dq, J = 14.8, 7.4 Hz, 4H), 1.10 (dd, J = 29.4, 26.2 Hz, 12H), 0.81 (t, J = 7.4 Hz, 6H). 13C
NMR (126 MHz, MeOD) δ 176.17, 156.64, 152.26, 143.34, 140.20, 135.93, 135.90, 129.44,
128.92, 126.85, 126.77, 125.13, 123.90, 121.81, 115.51, 49.64, 43.55, 36.99, 30.78, 30.36,
30.23, 30.11, 27.82, 26.96, 23.41, 14.11. MS (ESI) calculated for C56H68N10O2, m/z
912.5527, found 913.5886 (M + H)+ and 457.2974 (M + 2H)2+
Synthesis of Compound 11: tert-butyl 4-((4-amino-2-butyl-8-nitro-1H-imidazo[4,5-
c]quinolin-1-yl)methyl)benzylcarbamate
To a solution of 9 (500 mg, 1.16 mmol) in H2SO4, was added HNO3 (95 mg, 1.511 mmol).
The reaction mixture was stirred for 12 hours, followed by neutralization of sulfuric acid by
slow addition of sodium carbonate solution. EtOAc was added to this solution to extract the
compound, followed by washing with water/brine. The EtOAc fraction was then dried using
sodium sulfate and evaporated under vacuum to obtain the residue. The residue as dissolved
in MeOH and di-tert-butyl dicarbonate was added to it. The reaction was stirred for 30
minutes followed by removal of the solvent under vacuum to obtain the residue, which was
purified using column chromatography (7% MeOH/dichloromethane) to obtain the
compound 11 (200 mg, 34%).1H NMR (400 MHz, CDCl3) δ 8.67 (d, J = 2.5 Hz, 1H), 8.24 –
8.18 (m, 1H), 7.76 (d, J = 9.2 Hz, 1H), 7.28 (d, J = 7.0 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H),
5.95 (s, 2H), 5.76 (s, 2H), 4.87 (s, 1H), 4.29 (d, J = 5.5 Hz, 2H), 3.05 – 2.95 (m, 2H), 1.88
(dt, J = 15.5, 7.6 Hz, 2H), 1.51 (dd, J = 14.9, 7.3 Hz, 2H), 1.45 (s, 9H), 0.99 (t, J = 7.4 Hz,
3H). 13C NMR (101 MHz, CDCl3) δ 155.18, 153.33, 148.68, 141.64, 139.53, 133.91,
133.29, 128.41, 127.42, 127.25, 125.92, 121.27, 117.28, 113.88, 48.81, 44.09, 30.00, 28.35,
27.20, 22.54, 13.78. MS (ESI) calculated for C27H32N6O4, m/z 504.2485, found 505.2541
(M + H)+
Synthesis of Compound 11a: 1-(4-(aminomethyl) benzyl)-2-butyl-8-nitro-1H-imidazo[4,5-
c]quinolin-4-amine
Compound 11 (10 mg, 0.02 mmol) was dissolved in 1 mL solution of HCl/dioxane and
stirred for 12 hours. The solvent was then removed under vacuum and the residue was
washed with diethyl ether to afford the compound 11a in quantitative yields. 1H NMR (400
MHz, MeOD) δ 8.77 (d, J = 1.7 Hz, 1H), 8.47 – 8.41 (m, 1H), 7.98 (d, J = 9.1 Hz, 1H), 7.54
(d, J = 7.7 Hz, 2H), 7.30 (d, J = 7.7 Hz, 2H), 6.09 (s, 2H), 4.11 (s, 2H), 3.12 (t, J = 7.5 Hz,
2H), 1.98 – 1.88 (m, 2H), 1.59 – 1.49 (m, 2H), 1.00 (t, J = 7.3 Hz, 3H). 13C NMR (101
MHz, MeOD) δ 158.58, 150.14, 143.93, 137.46, 135.58, 135.36, 133.41, 129.86, 126.29,
125.89, 123.43, 119.40, 117.94, 112.44, 48.52, 42.36, 29.05, 26.44, 21.94, 12.71. MS (ESI)
calculated for C22H24N6O2, m/z 404.1961, found 405.1993 (M + H)+
Synthesis of Compound 12: tert-butyl 4-((4,8-diamino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
yl)methyl)benzylcarbamate
To a solution of 11 (190 mg, 0.377 mmol) in anhydrous MeOH, were added a catalytic
amount of Pd/C and the reaction mixture was subjected to hydrogenation at 60 psi hydrogen
pressure for 4 hours. The reaction mixture was then filtered through celite and the filtrate
was evaporated under vacuum to obtain the compound 12 (160 mg, 90%).1H NMR (400
MHz, MeOD) δ 7.49 (d, J = 8.8 Hz, 1H), 7.25 (d, J = 8.1 Hz, 2H), 7.14 (d, J = 2.3 Hz, 1H),
7.02 (d, J = 8.1 Hz, 2H), 6.97 (dd, J = 8.9, 2.4 Hz, 1H), 5.75 (s, 2H), 4.19 (s, 2H), 2.92 –
2.86 (m, 2H), 1.73 (dt, J = 15.4, 7.6 Hz, 2H), 1.43 (s, 9H), 0.92 (t, J = 7.4 Hz, 3H). 13C
NMR (101 MHz, MeOD) δ 154.56, 148.78, 142.89, 139.42, 136.71, 134.64, 133.60, 127.53,
125.80, 125.57, 118.16, 115.16, 103.42, 78.81, 43.18, 29.41, 27.33, 26.41, 22.01, 12.67. MS
(ESI) calculated for C27H34N6O2, m/z 474.2743, found 475.2733 (M + H)+
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Synthesis of Compound 12a: 1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-
c]quinoline-4,8-diamine
Compound 12 (10 mg, 0.021 mmol) was dissolved in 1 mL of HCl/dioxane solution and
stirred for 12 hours. The solvent was then removed under vacuum and the residue was
washed with diethyl ether to obtain the compound 12a in quantitative yields. 1H NMR (500
MHz, MeOD) δ 8.10 (s, 1H), 7.97 (d, J = 8.9 Hz, 1H), 7.67 (dd, J = 8.9, 2.2 Hz, 1H), 7.51
(d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.1 Hz, 2H), 6.04 (s, 2H), 4.12 (s, 2H), 3.03 (t, J = 7.6 Hz,
2H), 1.92 – 1.84 (m, 2H), 1.53 – 1.43 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (126
MHz, DMSO) δ 156.84, 147.83, 135.56, 134.67, 133.58, 129.58, 129.54, 126.08, 125.63,
124.97, 119.52, 113.08, 48.08, 41.64, 29.09, 26.17, 21.75, 13.66. MS (ESI) calculated for
C22H26N6, m/z 374.2219, found 375.2508 (M + H)+
Synthesis of Compound 13b: N1,N8-bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-
imidazo[4,5-c]quinolin-8-yl)octanediamide
To a solution of 12 (74 mg, 0.156 mmol) in anhydrous THF, were added triethylamine (39
mg, 0.39 mmol) and suberoyl chloride (15 mg, 0.07 mmol), and the reaction mixture was
stirred for 1 hour. The solvent was then removed under vacuum and the residue was purified
using column chromatography (20% MeOH/dichloromethane) to obtain the bis-N-Boc
protected compound which was then dissolved in 1 mL of HCl/dioxane solution and stirred
for 14 hours. The solvent was then removed under vacuum and the residue was washed with
diethyl ether to afford the compound 13b (12 mg, 19%; low yields were due to partial
acylation of the C4-NH2 which was found to be unstable). 1H NMR (500 MHz, MeOD) δ
8.62 (s, 2H), 7.70 – 7.65 (m, 2H), 7.61 (d, J = 9.0 Hz, 2H), 7.44 (d, J = 7.9 Hz, 4H), 7.18 (d,
J = 7.7 Hz, 4H), 5.93 (s, 4H), 4.07 (s, 4H), 2.98 (t, J = 7.5 Hz, 4H), 2.37 (dd, J = 16.6, 9.4
Hz, 4H), 1.85 (dt, J = 15.0, 7.6 Hz, 4H), 1.71 (s, 4H), 1.52 – 1.40 (m, 8H), 0.94 (t, J = 7.3
Hz, 6H). 13C NMR (126 MHz, MeOD) δ 174.75, 159.05, 149.75, 137.64, 137.34, 137.11,
134.51, 131.24, 130.93, 127.87, 126.22, 123.18, 119.97, 114.28, 111.99, 49.82, 43.82,
37.93, 30.27, 30.01, 27.81, 26.63, 23.36, 14.11. MS (ESI) calculated for C52H62N12O2, m/z
886.5119, found 909.5031 (M + Na+) and 444.2632 (M + 2H)2+.
Compounds 13a and 13c were synthesized similarly as described for compound 13b
13a—1H NMR (500 MHz, MeOD) δ 8.57 (s, 2H), 7.62 – 7.54 (m, 4H), 7.35 (d, J = 8.1 Hz,
4H), 7.10 (d, J = 8.0 Hz, 4H), 5.85 (s, 4H), 3.98 (s, 4H), 2.90 (t, J = 7.6 Hz, 4H), 2.36 (s,
4H), 1.77 (dt, J = 15.2, 7.6 Hz, 4H), 1.73 – 1.61 (m, 4H), 1.45 – 1.30 (m, 4H), 0.86 (t, J =
7.4 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 174.43, 159.11, 149.83, 137.66, 137.40,
137.16, 134.53, 131.33, 130.94, 127.89, 126.30, 123.18, 120.01, 114.38, 112.05, 49.82,
43.83, 37.65, 30.32, 27.81, 26.28, 23.37, 14.12. MS (ESI) calculated for C50H58N12O2, m/z
858.4806, found 859.4131 (M + H)+ and 430.2113 (M + 2H)2+.
13c—1H NMR (500 MHz, MeOD) δ 8.63 (s, 2H), 7.66 (d, J = 9.0 Hz, 2H), 7.58 (d, J = 8.9
Hz, 2H), 7.41 (d, J = 7.9 Hz, 4H), 7.15 (d, J = 7.8 Hz, 4H), 5.91 (s, 4H), 4.04 (s, 4H), 2.96
(t, J = 7.5 Hz, 4H), 2.33 (t, J = 7.1 Hz, 4H), 1.83 (dt, J = 15.2, 7.7 Hz, 4H), 1.65 (s, 4H),
1.44 (dq, J = 14.7, 7.3 Hz, 4H), 1.38 – 1.21 (m, 12H), 0.92 (t, J = 7.3 Hz, 6H). 13C NMR
(126 MHz, MeOD) δ 174.82, 159.01, 149.63, 137.68, 137.27, 137.10, 134.50, 131.24,
130.93, 129.84, 127.86, 126.00, 123.16, 120.01, 114.24, 111.92, 49.87, 43.82, 43.75, 38.04,
30.45, 30.34, 30.29, 30.23, 27.78, 26.78, 23.35, 14.11. MS (ESI) calculated for
C56H70N12O2, m/z 942.5745, found 943.5746 (M + H)+ and 472.2987 (M + 2H)2+.
TLR3/7/8 Reporter Gene assays (NF-κB induction)—The induction of NF-κB was
quantified using HEK-Blue-3, HEK-Blue-7 and HEK-Blue-8 cells as previously described
by us.5;7;11 HEK293 cells were stably transfected with human TLR3 (or human TLR7 or
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human TLR8), MD2, and secreted alkaline phosphatase (sAP), and were maintained in
HEK-Blue™ Selection medium containing zeocin and normocin. Stable expression of
secreted alkaline phosphatase (sAP) under control of NF-κB/AP-1 promoters is inducible by
the TLR3 (or TLR7 or TLR8) agonists, and extracellular sAP in the supernatant is
proportional to NF-κB induction. HEK-Blue cells were incubated at a density of ~105 cells/
ml in a volume of 80 μl/well, in 384-well, flat-bottomed, cell culture-treated microtiter
plates until confluency was achieved, and subsequently graded concentrations of stimuli.
sAP was assayed spectrophotometrically using an alkaline phosphatase-specific chromogen
(present in HEK-detection medium as supplied by the vendor) at 620 nm.
Antagonism assays were done as described by us earlier10 using the following agonists at a
constant concentration: TLR3 Poly(I:C) (10 ng/mL); TLR7: gardiquimod (1 μg/mL); TLR8:
CL075(1 μg/mL) mixed with graded concentrations of the test compounds.
IFN-α induction in human PBMCs—Aliquots (106 cells in 100 μL) of hPBMCs
isolated from blood obtained from healthy human donors after informed consent by
conventional Ficoll-Hypaque gradient centrifugation were stimulated for 12 h with graded
concentrations of test compounds. The supernatant was isolated by centrifugation, diluted
1:20, and IFN-α was assayed in triplicate using a high-sensitivity human IFN-α-specific
ELISA kit (PBL Interferon Source, Piscataway, NJ).
Cytokine and chemokine in human PBMCs—Aliquots (106 cells in 100 μL) of
hPBMCs isolated from blood obtained from healthy human donors after informed consent
by conventional Ficoll-Hypaque gradient centrifugation were stimulated for 12 h with
graded concentrations of test compounds. The supernatant was isolated by centrifugation,
diluted 1:20, and cytokines and chemokines were assayed in triplicate using analyte-specific
cytokine/chemokine bead array assays as reported by us previously.41
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TLR7 and TLR8 agonistic activities of the imidazoquinoline dimers in human TLR-specific
reporter gene assays.
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TLR7 (top) and TLR8 (bottom) antagonistic activities of the imidazoquinoline dimers 4a–b
and 6a–b in human TLR-specific reporter gene assays.
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IFN-α induction by select dimers in human peripheral blood mononuclear cells. IFN-α was
assayed by analyte specific ELISA after incubation of hPBMCs with graded concentrations
of the test compound for 12h. A representative experiment of three independent experiments
is shown.
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Inhibition of TLR7- and TLR8-mediated proinflammatory cytokine production in human
peripheral blood mononuclear cells by chloroquine or 4a. Proinflammatory cytokines were
assayed by cytokine bead array methods after incubation of hPBMCs with graded
concentrations of the test compound for 12h in the presence of 10 μg/ml of either CL075
(TLR8 agonist) or gardiquimod (TLR7 agonist). A representative experiment of three
independent experiments is shown.
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Inhibition of TLR7- and TLR8-mediated chemokine production in human peripheral blood
mononuclear cells by chloroquine or 4a. Chemokines were assayed by cytokine bead array
methods after incubation of hPBMCs with graded concentrations of the test compound for
12h in the presence of 10 μg/ml of either CL075 (TLR8 agonist) or gardiquimod (TLR7
agonist). A representative experiment of three independent experiments is shown.
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Schild plot analyses of inhibition of TLR7- and TLR8-induced activation. Experiments were
performed in checker-board format, using a liquid handler, in 384-well plates which
permitted the concentrations of both agonist and antagonist to be varied simultaneously
along the two axes of the plate. Either imidazoquinoline (TLR7-specific agonist) or CL075
(TLR8-specific agonist) was used at a starting concentration of 20 μg/mL, and were two-
fold diluted serially (along the rows). Next, 4a or chloroquine were two-fold diluted serially
in HEK detection medium (along columns). Reporter cells were then added, incubated, and
NF-κB activation measured as described in the text. A and A′ (Y-axis) are defined
respectively as the EC50 value in the absence of antagonist, and the EC50 values in the
presence of varying concentrations of antagonist.
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Syntheses of imidazoquinoline dimers linked at C2.
Reagents: i. Glutaric anhydride (n=2) or adipic anhydride (n=3), Et3N, THF, 110°C; ii. 1,
HBTU, Et3N, DMAP, DMF, 90 °C; iii. (a) 3-Chloroperoxybenzoic acid, CH2Cl2, CHCl3,
MeOH, 45 °C; (b) Benzoyl isocyanate, CH2Cl2, 45 °C; (c) NaOCH3, MeOH, 80 °C; iv. (a)
Suberoyl chloride (n=4) or dodecanedioyl dichloride (n=8), Et3N, THF; (b) NH3/MeOH,
150 °C.
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Syntheses of imidazoquinoline dimers linked at C4-NH2.
Reagents: i. 1,4-Diaminobutane (n=2) or 1,8-diaminooctane (n=4) or 1,10-diaminodecane
(n=6) or 1,12-diaminododecane (n=10), MeOH, 140 °C;
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Syntheses of imidazoquinoline dimers linked at N1-(4-aminomethylene)benzyl.
Reagents: i. Adipoyl chloride (n=1) or suberoyl chloride (n=3) or dodecanedioyl dichloride
(n=7), Et3N, THF.
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Syntheses of imidazoquinoline dimers linked at C8-NH2.
Reagents: i. (a) HNO3, H2SO4; (b) (Boc)2O, Et3N, MeOH; ii. H2, Pt/C, MeOH, 60 psi; iii.
(a) Adipoyl chloride (n=2) or suberoyl chloride (n=4) or dodecanedioyl dichloride (n=8),
Et3N, THF; (b) HCl/dioxane, iv. HCl/dioxane.
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